Literature DB >> 17635594

Episodic dural stimulation in awake rats: a model for recurrent headache.

Michael L Oshinsky1, Sumittra Gomonchareonsiri.   

Abstract

OBJECTIVES: To model, in rats, the development of chronic trigeminal nociceptive hypersensitivity seen in patients with recurrent headache.
BACKGROUND: Pathophysiology studies suggest that patients with recurrent migraine headache experience repeated bouts of dural nociceptor activation. In some patients, the severity and frequency of headache attacks increase over time. Patients with recurrent headache are hypersensitive to nitric oxide donors, such as glyceryl trinitrate (GTN). Current trigeminal pain models do not reflect the repeated episodic nature of dural nociceptor activation in patients with recurrent headache. Repeated nociceptor activation creates long-lasting changes in the periphery and brain due to activity-dependent neuronal plasticity. An animal model of repeated activation of dural nociceptors will facilitate the study of the physiological changes caused by repeated, episodic pain and the factors important for the transition of episodic to chronic migraine.
METHODS: We induced dural inflammation by infusing an inflammatory soup (IS) through a cannula on the dura in awake behaving rats. This was repeated 3 times per week for up to 4 weeks. Periorbital pressure sensory testing was used to monitor the change in trigeminal sensitivity. Rats were challenged with GTN to test the hypothesis that many dural stimulations are required to model the hypersensitivity of migraine patients. Quantitative trigeminal sensory testing and microdialysis in the trigeminal nucleus caudalis (TNC) were used to measure GTN hypersensitivity.
RESULTS: Multiple infusions of IS (>8), over weeks, induced a long-lasting decrease in periorbital pressure thresholds that lasted >3 weeks after the last infusion. In contrast, IS infusion in IS-naive rats and those that received 3 IS infusions produced only short-lasting decreases in periorbital pressure thresholds. Rats that received more than 8 IS infusions showed a marked increase in their neurochemical and behavioral responses to GTN. In these rats, GTN induced a decrease in periorbital von Frey thresholds that lasted >5 hours. In contrast, in rats that received only 3 IS infusions, GTN caused a threshold decrease for 1.5 hour. In vivo microdialysis in the TNC showed that GTN increased extracellular glutamate levels in rats with more than 8 IS infusions to 7.7 times the basal levels. In IS-naive rats and those that received only 3 IS infusions, the extracellular glutamate levels rose to only 1.7 and 1.9 times the basal level, respectively.
CONCLUSIONS: Repeated IS stimulation of the dura produces a chronic state of trigeminal hypersensitivity and potentiates the response to GTN. This hyperresponsiveness outlasts the last IS infusion and is the basis of our rat model of recurrent headache. This model can be used to study the changes in the brain and periphery induced by repeated trigeminovascular nociceptor activation and has the potential to elucidate the mechanisms for the transition of episodic to chronic headache.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17635594      PMCID: PMC4029495          DOI: 10.1111/j.1526-4610.2007.00871.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  50 in total

1.  A new model of visceral pain and referred hyperalgesia in the mouse.

Authors:  J M A Laird; L Martinez-Caro; E Garcia-Nicas; F Cervero
Journal:  Pain       Date:  2001-06       Impact factor: 6.961

2.  Recurrent extratrigeminal stabbing and burning sensation with allodynia in a migraine patient.

Authors:  E J Piovesan; B W Young; L C Werneck; P A Kowacs; M L Oshinsky; S D Silberstein
Journal:  Cephalalgia       Date:  2003-04       Impact factor: 6.292

3.  Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks.

Authors:  P Sarchielli; A Alberti; M Codini; A Floridi; V Gallai
Journal:  Cephalalgia       Date:  2000-12       Impact factor: 6.292

Review 4.  Neuronal plasticity: increasing the gain in pain.

Authors:  C J Woolf; M W Salter
Journal:  Science       Date:  2000-06-09       Impact factor: 47.728

Review 5.  Animal models of migraine: looking at the component parts of a complex disorder.

Authors:  A Bergerot; P R Holland; S Akerman; T Bartsch; A H Ahn; A MaassenVanDenBrink; U Reuter; C Tassorelli; J Schoenen; D D Mitsikostas; A M J M van den Maagdenberg; P J Goadsby
Journal:  Eur J Neurosci       Date:  2006-09       Impact factor: 3.386

6.  A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks.

Authors:  L L Thomsen; C Kruuse; H K Iversen; J Olesen
Journal:  Eur J Neurol       Date:  1994-09       Impact factor: 6.089

7.  Behavioral evidence of trigeminal neuropathic pain following chronic constriction injury to the rat's infraorbital nerve.

Authors:  B P Vos; A M Strassman; R J Maciewicz
Journal:  J Neurosci       Date:  1994-05       Impact factor: 6.167

8.  Quantitative assessment of tactile allodynia in the rat paw.

Authors:  S R Chaplan; F W Bach; J W Pogrel; J M Chung; T L Yaksh
Journal:  J Neurosci Methods       Date:  1994-07       Impact factor: 2.390

Review 9.  The role of nitric oxide in vascular headache.

Authors:  Paul-Hugo M van der Kuy; Joseph J Lohman
Journal:  Pharm World Sci       Date:  2003-08

10.  Evidence for serotonin (5-HT)1B, 5-HT1D and 5-HT1F receptor inhibitory effects on trigeminal neurons with craniovascular input.

Authors:  P J Goadsby; J D Classey
Journal:  Neuroscience       Date:  2003       Impact factor: 3.590

View more
  83 in total

Review 1.  Update on medication-overuse headache.

Authors:  Milena De Felice; Michael H Ossipov; Frank Porreca
Journal:  Curr Pain Headache Rep       Date:  2011-02

2.  Sensitization of the trigeminovascular system following environmental irritant exposure.

Authors:  Phillip Edward Kunkler; LuJuan Zhang; Jessica Joan Pellman; Gerry Stephen Oxford; Joyce Harts Hurley
Journal:  Cephalalgia       Date:  2015-02-27       Impact factor: 6.292

3.  Dissociation between CSD-Evoked Metabolic Perturbations and Meningeal Afferent Activation and Sensitization: Implications for Mechanisms of Migraine Headache Onset.

Authors:  Jun Zhao; Dan Levy
Journal:  J Neurosci       Date:  2018-04-27       Impact factor: 6.167

Review 4.  TRPM8 and Migraine.

Authors:  Greg Dussor; Yu-Qing Cao
Journal:  Headache       Date:  2016-09-16       Impact factor: 5.887

5.  Mast cell degranulation distinctly activates trigemino-cervical and lumbosacral pain pathways and elicits widespread tactile pain hypersensitivity.

Authors:  Dan Levy; Vanessa Kainz; Rami Burstein; Andrew M Strassman
Journal:  Brain Behav Immun       Date:  2011-10-12       Impact factor: 7.217

6.  Behavioral effects and mechanisms of migraine pathogenesis following estradiol exposure in a multibehavioral model of migraine in rat.

Authors:  Lydia M M Vermeer; Eugene Gregory; Michelle K Winter; Kenneth E McCarson; Nancy E J Berman
Journal:  Exp Neurol       Date:  2014-09-28       Impact factor: 5.330

Review 7.  Update on animal models of migraine.

Authors:  Marcela Romero-Reyes; Simon Akerman
Journal:  Curr Pain Headache Rep       Date:  2014-11

Review 8.  Therapeutic use of botulinum toxin in migraine: mechanisms of action.

Authors:  Roshni Ramachandran; Tony L Yaksh
Journal:  Br J Pharmacol       Date:  2014-09       Impact factor: 8.739

9.  Sustained morphine-induced sensitization and loss of diffuse noxious inhibitory controls in dura-sensitive medullary dorsal horn neurons.

Authors:  Akiko Okada-Ogawa; Frank Porreca; Ian D Meng
Journal:  J Neurosci       Date:  2009-12-16       Impact factor: 6.167

10.  A novel method for modeling facial allodynia associated with migraine in awake and freely moving rats.

Authors:  Julie Wieseler; Amanda Ellis; David Sprunger; Kim Brown; Andrew McFadden; John Mahoney; Niloofar Rezvani; Steven F Maier; Linda R Watkins
Journal:  J Neurosci Methods       Date:  2009-10-29       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.